A randomized double-blind placebo-controlled study of Pu'er tea (ae™®ae′±eOE) extract on the regulation of metabolic syndrome

被引:38
作者
Chu Song-ling [1 ]
Fu Hong [1 ]
Yang Jin-xia [1 ]
Liu Geng-xin [1 ]
Dou Pan [1 ]
Zhang Liang [2 ]
Tu Peng-fei [2 ]
Wang Xue-mei [1 ]
机构
[1] Beijing Med Univ, Integrat Chinese & Western Med Lab, Hosp 1, Grad Sch Integrat Chinese & Western Med, Beijing 100034, Peoples R China
[2] Peking Univ, State Key Lab Nat & Biomimet Drugs, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
关键词
tea; metabolic syndrome; randomized controlled clinical study; INSULIN-RESISTANCE;
D O I
10.1007/s11655-011-0781-4
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
To explore the regulative efficacy of Pu'er tea (ae (TM)(R) ae '+/- eOE ) extract on metabolic syndrome. Ninety patients with metabolic syndrome were randomly divided into two groups, the intervention group administered with Pu'er tea extract, and the placebo group with placebo capsules. After 3 months' treatment, body mass index, waist hip ratio, blood lipids, blood sugar, immune and inflammatory index, and oxidation index of the patients with metabolic syndrome were tested and analyzed. In the intervention group, the body mass index, waist-hip ratio, fasting and 2 h postprandial blood glucose, serum total cholesterol, triglycerides, low density lipoprotein and apolipoprotein B-100 all decreased in the patients with metabolic syndrome, and also the high-density lipoprotein level increased and apolipoprotein A-1 showed the tendency to increase. Serum C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 were decreased in the intervention group. Interleukin-10 level was increased, MDA was decreased and superoxide dismutase was increased. Compared with before treatment and the placebo group, there were significant differences (P < 0.05, P < 0.01). Pu'er tea demonstrated excellent potential in improving central obesity, adjusting blood lipid, lowering blood sugar, regulating immunity and resisting oxidation. It can adjust the metabolic syndrome of different clinical phenotypes to different degrees, and is ideally fit for early prevention of metabolic syndrome.
引用
收藏
页码:492 / 498
页数:7
相关论文
共 16 条
[1]  
Cardoso-Saldaña G, 2007, J PEDIATR ENDOCR MET, V20, P797
[2]   The metabolic syndrome [J].
Eckel, RH ;
Grundy, SM ;
Zimmet, PZ .
LANCET, 2005, 365 (9468) :1415-1428
[3]   OXYGEN FREE-RADICALS AND MYOCARDIAL DAMAGE - PROTECTIVE ROLE OF THIOL-CONTAINING AGENTS [J].
FERRARI, R ;
CECONI, C ;
CURELLO, S ;
CARGNONI, A ;
ALFIERI, O ;
PARDINI, A ;
MARZOLLO, P ;
VISIOLI, O .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 :S95-S105
[4]   Prevalence of the metabolic syndrome and overweight among adults in China [J].
Gu, DF ;
Reynolds, K ;
Wu, XG ;
Chen, F ;
Duan, XF ;
Reynolds, RF ;
Whelton, PK ;
He, J .
LANCET, 2005, 365 (9468) :1398-1405
[5]   EFFECTS OF RECOMBINANT HUMAN EXTRACELLULAR-SUPEROXIDE DISMUTASE TYPE-C ON MYOCARDIAL REPERFUSION INJURY IN ISOLATED COLD-ARRESTED RAT HEARTS [J].
HATORI, N ;
SJOQUIST, PO ;
MARKLUND, SL ;
PEHRSSON, SK ;
RYDEN, L .
FREE RADICAL BIOLOGY AND MEDICINE, 1992, 13 (02) :137-142
[6]  
Jiang XinFeng Jiang XinFeng, 2009, Journal of Yunnan Agricultural University, V24, P705
[7]   Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? [J].
Kraja, Aldi T. ;
Province, Michael A. ;
Arnett, Donna ;
Wagenknecht, Lynne ;
Tang, Weihong ;
Hopkins, Paul N. ;
Djousse, Luc ;
Borecki, Ingrid B. .
NUTRITION & METABOLISM, 2007, 4 (1)
[8]   Oxidative stress markers in Korean subjects with insulin resistance syndrome [J].
Lee, KU .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2001, 54 :S29-S33
[9]  
LI XJ, 2006, GUIDING J TRADIT CHI, V12, P9
[10]  
Society C D., 2004, CHIN J DIABETES, V12, P156, DOI DOI 10.1002/IJG0.12802